Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Director · Chief Executive Officer | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 666,568 |
Ending reported balance
After 2026-10-01 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 30,000 · Balance 696,568 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. Row 2 · 2026-10-01 · Sale · Disposed 3,525 · Balance 693,043 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.93 to $111.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-10-01 · Sale · Disposed 5,506 · Balance 687,537 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.92 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-10-01 · Sale · Disposed 4,876 · Balance 682,661 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.95 to $113.88 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-10-01 · Sale · Disposed 7,601 · Balance 675,060 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-10-01 · Sale · Disposed 8,230 · Balance 666,830 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.94 to $115.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2026-10-01 · Sale · Disposed 262 · Balance 666,568 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.16 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2029-11-13 | Direct | 60,000 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 30,000 · Balance 60,000 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. F8: The shares underlying this stock option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.93 to $111.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.92 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.95 to $113.88 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.94 to $115.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.16 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The shares underlying this stock option are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2021 Filed Jun 11, 2021 20:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 23,009 | $2.08 | $47,858.72 |
DisclosureSEC source: 0000899243-21-023228 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2021 Filed Jun 9, 2021 21:54 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,752 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-022812 · doc4.xml · derivative · entry 9 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,734 Underlying: Common Stock · 5,752 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| June 09, 2021 Filed Jun 9, 2021 21:54 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,752 | $50.02 | $287,721.37 |
DisclosureSEC source: 0000899243-21-022812 · doc4.xml · nonDerivative · entry 6 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.105. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 09, 2021 Filed Jun 9, 2021 21:54 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 5,752 | $2.08 | $11,964.16 |
DisclosureSEC source: 0000899243-21-022812 · doc4.xml · nonDerivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 21:54 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 270 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-022812 · doc4.xml · derivative · entry 8 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,486 Underlying: Common Stock · 270 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 21:54 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 270 | $50.00 | $13,500.00 |
DisclosureSEC source: 0000899243-21-022812 · doc4.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 21:54 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 270 | $2.08 | $561.60 |
DisclosureSEC source: 0000899243-21-022812 · doc4.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 21:54 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,724 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-022812 · doc4.xml · derivative · entry 7 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,756 Underlying: Common Stock · 12,724 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 21:54 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 12,724 | $50.14 | $638,039.89 |
DisclosureSEC source: 0000899243-21-022812 · doc4.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 21:54 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 12,724 | $2.08 | $26,465.92 |
DisclosureSEC source: 0000899243-21-022812 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2021 Filed May 19, 2021 21:56 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-019964 · doc4.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,424 Underlying: Common Stock · 15,000 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| May 19, 2021 Filed May 19, 2021 21:56 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 15,000 | $2.08 | $31,200.00 |
DisclosureSEC source: 0000899243-21-019964 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2021 Filed May 14, 2021 21:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,245 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-019551 · doc4.xml · derivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,480 Underlying: Common Stock · 8,245 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| May 12, 2021 Filed May 14, 2021 21:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8,245 | $50.05 | $412,677.09 |
DisclosureSEC source: 0000899243-21-019551 · doc4.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 12, 2021 Filed May 14, 2021 21:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 8,245 | $2.08 | $17,149.60 |
DisclosureSEC source: 0000899243-21-019551 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,768 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-016981 · doc4.xml · derivative · entry 9 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,725 Underlying: Common Stock · 2,768 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,768 | $40.18 | $111,229.04 |
DisclosureSEC source: 0000899243-21-016981 · doc4.xml · nonDerivative · entry 6 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 2,768 | $2.08 | $5,757.44 |
DisclosureSEC source: 0000899243-21-016981 · doc4.xml · nonDerivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 680 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-016981 · doc4.xml · derivative · entry 8 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,493 Underlying: Common Stock · 680 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 680 | $40.01 | $27,207.55 |
DisclosureSEC source: 0000899243-21-016981 · doc4.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 680 | $2.08 | $1,414.40 |
DisclosureSEC source: 0000899243-21-016981 · doc4.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,959 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-016981 · doc4.xml · derivative · entry 7 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,173 Underlying: Common Stock · 10,959 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 10,959 | $40.26 | $441,181.94 |
DisclosureSEC source: 0000899243-21-016981 · doc4.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.78. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 10,959 | $2.08 | $22,794.72 |
DisclosureSEC source: 0000899243-21-016981 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2021 Filed Apr 19, 2021 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-016272 · doc4.xml · derivative · entry 8 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,424 Underlying: Common Stock · 6,000 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 19, 2021 Filed Apr 19, 2021 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 653 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-016272 · doc4.xml · derivative · entry 7 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,132 Underlying: Common Stock · 653 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| April 19, 2021 Filed Apr 19, 2021 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 6,000 | $2.08 | $12,480.00 |
DisclosureSEC source: 0000899243-21-016272 · doc4.xml · nonDerivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2021 Filed Apr 19, 2021 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 653 | $40.00 | $26,120.65 |
DisclosureSEC source: 0000899243-21-016272 · doc4.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 19, 2021 Filed Apr 19, 2021 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 653 | $2.08 | $1,358.24 |
DisclosureSEC source: 0000899243-21-016272 · doc4.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,940 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-016272 · doc4.xml · derivative · entry 6 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,785 Underlying: Common Stock · 4,940 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,940 | $40.29 | $199,038.53 |
DisclosureSEC source: 0000899243-21-016272 · doc4.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:12 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 4,940 | $2.08 | $10,275.20 |
DisclosureSEC source: 0000899243-21-016272 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 13, 2021 22:39 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-015653 · doc4.xml · derivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,424 Underlying: Common Stock · 15,000 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 13, 2021 Filed Apr 13, 2021 22:39 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 15,000 | $2.08 | $31,200.00 |
DisclosureSEC source: 0000899243-21-015653 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2021 Filed Apr 12, 2021 22:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,267 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-015543 · doc4.xml · derivative · entry 12 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,725 Underlying: Common Stock · 15,267 shares Expires 2019-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| April 12, 2021 Filed Apr 12, 2021 22:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,905 | $33.32 | $163,414.49 |
DisclosureSEC source: 0000899243-21-015543 · doc4.xml · nonDerivative · entry 9 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.92 to $33.88. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 12, 2021 Filed Apr 12, 2021 22:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 10,362 | $32.29 | $334,566.18 |
DisclosureSEC source: 0000899243-21-015543 · doc4.xml · nonDerivative · entry 8 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,104 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.92 to $32.915. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 12, 2021 Filed Apr 12, 2021 22:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 15,267 | $2.08 | $31,755.36 |
DisclosureSEC source: 0000899243-21-015543 · doc4.xml · nonDerivative · entry 7 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 22:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,794 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-015543 · doc4.xml · derivative · entry 11 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,992 Underlying: Common Stock · 22,794 shares Expires 2019-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 22:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,742 | $34.19 | $127,923.26 |
DisclosureSEC source: 0000899243-21-015543 · doc4.xml · nonDerivative · entry 6 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.985 to $34.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 22:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 19,052 | $33.58 | $639,827.13 |
DisclosureSEC source: 0000899243-21-015543 · doc4.xml · nonDerivative · entry 5 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,941 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.985 to $33.975. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 22:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 22,794 | $2.08 | $47,411.52 |
DisclosureSEC source: 0000899243-21-015543 · doc4.xml · nonDerivative · entry 4 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 22:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,939 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-21-015543 · doc4.xml · derivative · entry 10 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,786 Underlying: Common Stock · 9,939 shares Expires 2019-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones. Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 22:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,323 | $35.62 | $82,747.82 |
DisclosureSEC source: 0000899243-21-015543 · doc4.xml · nonDerivative · entry 3 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,199 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.38 to $35.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 22:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,616 | $34.81 | $265,084.02 |
DisclosureSEC source: 0000899243-21-015543 · doc4.xml · nonDerivative · entry 2 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,522 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.235 to $35.195. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 22:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 9,939 | $2.08 | $20,673.12 |
DisclosureSEC source: 0000899243-21-015543 · doc4.xml · nonDerivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:54 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 375,000 | $0.00 Strike: $48.46 | $0.00 |
DisclosureSEC source: 0000899243-21-009412 · doc4.xml · derivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2031-02-28 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments over three (3) years following the Grant Date, with the first installment vesting on April 1, 2021. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 22:26 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 125,399 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023237 · doc4.xml · derivative · entry 1 Mainolfi Nello · CIK 0001821189 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,399 Underlying: Common Stock · 125,399 shares Expires 2030-08-19 F1 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal monthly installments over four (4) years commencing on the date of the Registration Statement Effectiveness. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.